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PRE-PROCEDURAL TIMI FLOW IN STEMI PATIENTS
Antiplatelet drug use on admission was associated with pre-procedural TIMI flow. The patency of the IRA in patients with STEMI was related to procedural success and decreased enzymatic infarct size, fatal arrhythmic events, and in-hospital mortality.
(Int Heart J 2018; 59: 920-925) Key words: Infarct-related artery, Percutaneous coronary intervention, In-hospital clinical outcomes, Antiplatelet drug P rimary percutaneous coronary intervention (PCI) has been shown to improve the outcome of patients with ST-segment elevation myocardial infarction (STEMI). [1] [2] [3] [4] However, the time delay required for reperfusion of the infarct-related artery (IRA) has been associated with worse outcomes. 5, 6) When reperfusion occurs before primary PCI, outcomes are strikingly better with less cardiogenic shock, improved procedural outcomes, smaller infarct size, better preservation of left ventricular function, and reduced mortality. 7) Previous studies have shown that various prothrombotic and inflammatory markers including the neutrophil to lymphocyte ratio, platelet count and reactivity, mean platelet volume, and uric acid have been associated with the patency of IRA in patients with STEMI before primary PCI. [8] [9] [10] However, factors associated with preprocedural Thrombolysis In Myocardial Infarction (TIMI) flow have not been fully investigated. The aim of this study was to examine factors associated with preprocedural TIMI flow in patients with STEMI.
Methods

Study design and subjects:
The Japanese registry of acute Myocardial INfarction diagnosed by Universal dEfiniTion (J-MINUET) is a prospective multicenter registry conducted at 28 Japanese medical institutions.
11) The J-MINUET study enrolled 3,283 consecutive patients with AMI who were admitted to a participating institution within 48 hours of symptom onset between July 2012 and March 2014. The diagnosis of AMI was based on the ESC/ACC Foundation (ACCF)/American Heart Association (AHA)/World Heart Federation Task Force for the Universal Definition of Myocardial Infarction. 12) AMI was diagnosed by the rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile of the upper reference limit observed together with evidence of myocardial ischemia with at least one of the following: symptoms of ischemia, electrocardiography (ECG) changes indicative of new ischemia, development of pathological Q waves in the ECG, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormalities. STEMI was diagnosed in the presence of a new ST elevation at the J point in at least two contiguous leads !2 mm (0.2 mV) in men or !1.5 mm (0.15 mV) in women in leads V2-V3 and/or !1 mm (0.1 mV) in other contiguous chest leads or limb leads. 13, 14) A new left bundle branch block was considered as an STEMI equivalent. There were 2,262 patients (68.9%) with STEMI, and 2,182 patients underwent emergent or urgent coronary angiography (CAG). The antegrade blood flow of the IRA was evaluated with the use of TIMI criteria.
Patients were evaluated for baseline clinical characteristics, laboratory data, and medications on admission. Clinical events were collected at the time of discharge.
The endpoints were in-hospital mortality and major adverse cardiac events, defined as a composite of all cause death, cardiac failure, ventricular tachycardia (VT) and/or ventricular fibrillation (VF), and bleeding during hospitalization. Cardiac failure was defined as congestive heart failure and/or cardiogenic shock that required treatment. We examined the impact of pre-procedural TIMI flow on in-hospital outcomes and the factors associated with preprocedural TIMI flow. The present study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the ethics committee of each participating institution. Statistical analysis: Continuous variables are expressed as the mean ± standard deviation and were compared using the unpaired t-test or the Wilcoxon rank sum test. Categorical variables are presented as numbers and frequencies and were compared using the chi-square test. Univariate and multivariate logistic regression models were used to assess the determinant of pre-procedural TIMI flow grade 3, and all significant parameters in the univariate analysis were selected in the multivariate model. The candidate variables were age, male gender, hypertension, dyslipidemia, diabetes mellitus, current smoker, chronic kidney disease, systolic blood pressure, heart rate, platelets, uric acid, high-density lipoprotein cholesterol, antiplatelet use, beta-blocker use, angiotensin receptor blocker use, statin use, and onset to balloon time. A P-value of < 0.05 was used to indicate statistical significance. All analyses were performed using JMP version 12.0.1 for Windows (SAS, NC, USA).
Results
Baseline characteristics: Our study included 2,182 patients with STEMI who underwent emergent or urgent CAG. Pre-intervention TIMI flows were 0, 1, 2, and 3 in 1,296 (59.4%), 242 (11.1%), 335 (15.4%), and 309 (14.2%) patients, respectively. Altogether, PCI was performed in 2,097 patients; in 23 patients, it was performed by coronary artery bypass graft surgery and in 62 by conservative medical treatment. Patients were divided into two groups according to the pre-procedural TIMI flow (TIMI flow grade 0-2, or 3).
Baseline characteristics according to the preprocedural TIMI flow are shown in Table I . Demographic characteristics were similar between the groups. Patients with pre-procedural TIMI flow grade 3 demonstrated a higher systolic blood pressure (P < 0.001) and heart rate on admission (P = 0.008). Antiplatelet drug use (P = Hashimoto, ET AL 0.005) or beta-blocker use (P = 0.040) on admission was associated with pre-procedural TIMI flow. Procedural characteristics and outcomes: Procedural characteristics and outcomes determined by pre-procedural TIMI flow are shown in Table II . Pre-procedural TIMI flow grade 3 was related to post-procedural TIMI flow grade 3 (P < 0.001). Post-procedural TIMI flow grade 3 was achieved in 98% of patients with pre-procedural TIMI flow grade 3. In-hospital outcomes: In-hospital outcomes are shown in Table III . Pre-procedural TIMI flow grade 3 was associated with a decrease in VT/VF (P = 0.049), and lower inhospital mortality (P = 0.020). The peak creatine kinase (CK) level was significantly lower in patients with preprocedural TIMI flow grade 3 (P < 0.001).
Factors associated with pre-procedural TIMI flow grade 3 in IRA:
In multiple logistic regression analysis, systolic blood pressure, heart rate, and antiplatelet use on admission were significantly associated with preprocedural TIMI flow grade 3 (Table IV) .
Discussion
The main findings of the present study were as follows: (1) pre-procedural TIMI flow grade 3 in an IRA was associated with post-procedural TIMI flow grade 3 and better in-hospital outcomes; and (2) history of antiplatelet use was an independent determinant of preprocedural TIMI flow grade 3. Our data demonstrated that pre-procedural TIMI flow grade 3 was associated with procedural success and decreased peak CK, in-hospital mortality, and VT/VF compared with pre-procedural TIMI flow grade 0-2. Previous studies have shown the impact of pre-procedural TIMI flow on the outcome of patients with STEMI treated by primary PCI. Stone, et al. found pre-procedural TIMI flow grade 3 to be an independent determinant of survival [odds ratio (OR) 2.1, P = 0.04]. 15) De Luca, et al confirmed that pre-procedural TIMI flow grade 3 was an independent predictor of one-year survival in high-risk patients with AMI treated by primary PCI. 16) These results were further supported by the CADILLAC and HORIZONS-AMI Trials, 17) in which baseline TIMI flow grade 3 was a strong predictor of one-year survival. Factors associated with pre-procedural TIMI flow grade 3: High systolic blood pressure and fast heart rate on admission were significantly associated with preprocedural TIMI flow grade 3. Systolic blood pressure might increase because of myocardial reperfusion. 18) A complete atrioventricular block was more frequently administered in patients with pre-procedural TIMI flow grade 0-2 compared to those with grade 3 (5.03% versus 2.27%, P = 0.033), which may have been related to the higher heart rate in the TIMI flow grade 3 groups. Unlike our results, the independent predictors of pre-procedural TIMI flow grade 3 were diabetes, longer delay to PCI, smoking, and more extensive coronary disease in the CA-DILLAC and HORIZONS-AMI Trials. 17) In addition, other previous studies have shown that various pro-thrombotic and inflammatory markers including the neutrophil to lymphocyte ratio, platelet count and reactivity, mean platelet volume, and uric acid have been associated with the patency of IRA in patients with STEMI before primary PCI. [8] [9] [10] Although the precise reasons for the difference in the factors of pre-PCI coronary flow between the present study and previous studies are unknown, differences in the cohorts, study definition, and patient backgrounds may have been the causes.
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The use of an antiplatelet drug on admission was also associated with pre-procedural TIMI flow grade 3. Although Robinson, et al. reported that patients with STEMI who used beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, statins, and aspirin before the event had a higher likelihood of having a patent IRA than those who did not use these medications, 19) the medications associated with pre-procedural TIMI flow have not been fully investigated. Antiplatelet therapy prevents serious vascular events among a wide range of patients at high risk of occlusive vascular events. [20] [21] [22] In a secondary prevention trial, the Antithrombotic Trialists concluded that low-dose aspirin yielded a greater absolute reduction in serious vascular (6.7% versus 8.2% per year, P < 0.001) and coronary (4.3% versus 5.3% per year, P < 0.001) events. 22) Several studies have reported that prehospital administration of glycoprotein IIb/IIIa inhibitors in patients undergoing PCI for STEMI was associated with improved coronary reperfusion and outcomes. 23, 24) However, early inhibition of the platelet ADP-receptor with a high loading dose of 600 mg clopidogrel administered in the prehospital phase in patients with STEMI scheduled for primary PCI did not increase the pre-PCI patency of IRA. 25) In addition, prehospital administration of ticagrelor in patients with STEMI did not improve pre-PCI coronary reperfusion in the ATLANTIC trial. 26) This result might be explained by the short time frame between the ADP receptor antagonist loading dose and angiography, with a median of 47 minutes in the CIPAMI trial and 48 minutes in the ATLANTIC trial. There might not have been enough time for the clopidogrel or ticagrelor to show an antiplatelet effect. In the present study, a history of antiplatelet drug use was able to obtain an antiplatelet effect sufficient to improve pre-PCI patency of IRA. Yonetsu, et al. reported that optical coherence tomography detected less frequent thrombi and smaller thrombus volume at the culprit lesion in patients taking aspirin before their first presentation with acute coronary syndrome than in those without prior aspirin use, 27) which is consistent with our findings. Antiplatelet therapy may improve pre-PCI coronary reperfusion and clinical outcomes in addition to the effects of secondary prevention. Study limitations: The present study has several limitations. First, there might have been a selection bias for enrolled patients, because the J-MINUET study was not a population-based study. Second, although we collected information on outpatient medications, we did not collect information on the duration of therapy before admission. Third, we did not have any data on pre-procedural anticoagulant use, which was a potentially influential factor in pre-procedural TIMI flow.
Conclusions
We found that a history of antiplatelet drug use was associated with TIMI flow grade 3. The patency of IRA in patients with STEMI was related to procedural success and decreased enzymatic infarct size, VT/VF, and inhospital mortality.
